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Summary The expression of bcl-2 was studied in normal ovanres and in ovarian tumours by immunohis-
tochemical analysis. Normal epithelium was strongly stained in all nine examined ovaries. In comparison. all
tumour groups showed a substantially decreased tumour cell expression of the same order of magnitude. Thus.
benign tumour cells were weakly stained in two and unstained in two samples, while the remaining eight
showed strong expression. Of ten borderline samples. one was unstained and five had weakly and four strongly
bcl-2 positive tumour cells. Finally. 24 of 50 malignant tumours showed strong staining, while weak or no
expression in tumour cells was found in 16 and 10 samples respectively. The reduced staining deviated
significantly from normal ovary for both borderline (P = 0.02) and malignant groups (P = 0.01). Tumour cell
staining with the bcl-2 antibody was significantly reduced when tumour mass had to be left behind compared
with those with no visible remaining tumour (P = 0.03 and 0.003 for weakly and strongly stained tumours
respectively). The expression of bcl-2 in malignant tumour cells was inversely correlated with the expression of
p53. Bcl-2 expression was correlated with survival with significantly reduced survival in weakly (P = 0.02) and
unstained (P<0.001) groups compared with those patients having strongly stained malignant tumour cells.
This correlation between the presence of bcl-2 and survival was maintained in the subgroups of patients with
advanced disease or with residual tumour bulk and was also the case in patients having p53-positive tumours.
Our results indicate an inhibitory role of bcl-2 in development and progression of ovarian tumours.
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Epithelial ovarian cancer is the leading cause of death in
gynaecological malignancy (Petterson, 1991). Treatment is
aggressive primary debulking surgery followed by
chemotherapy in advanced disease. Although several different
clinical trials have been carried out, only a marginal increase
in survival has been obtained. Our lack of basic knowledge
of the tumour biology underlying this disease presents a
major obstacle to improving treatment, as well as to estab-
lishing treatment modalities based on aetiological and
pathogenetic evidence. Only recently have studies on the role
of growth factors in ovarian cancer been carried out, and
hitherto two growth factor receptors of prognostic value have
been found which appear to be involved in some facet of
ovarian tumour development (Slamon et al., 1989; Henriksen
et al., 1993).
While much effort has concentrated on examining
mechanisms of increased proliferation in cancer development,
the regulation of physiological cell death has only recently
come into focus. Cell suicide is a well-known fundamental
feature in different biological settings (for recent reviews see
Raff, 1992; Wyllie 1993; Kerr and Winterford, 1994). The
ultrastructural changes which deviate from the necrotic pro-
cess were described in 1972 and the process termed apoptosis
(Kerr et al., 1972). It provides an efficient mechanism for
eliminating cells that are unwanted for some reason and may
furthermore be of significance for keeping cell numbers at
constant levels in different organs.
Bcl-2 is an oncoprotein, which apparently inhibits apop-
tosis (McDonnell et al., 1989; Hockenbery et al., 1990). In a
few studies on protein expression in various disorders both
inhibitory and stimulatory properties towards carcinogenesis
were indicated (Castle et al., 1993; Colombel et al., 1993;
Leek et al., 1994). In a recent study in non-small-cell lung
cancer bcl-2 expression was correlated with survival (Pezella
et al., 1993). Thus, in contrast to the teleological viewpoint
that decreased apoptosis, which correlates to high bcl-2 ex-
pression, should contribute to tumour development by in-
creasing cell mass and decreasing 'cell-cleaning' expression of
the anti-apoptotic protein seemed to improve survival.
To further examine its role in tumour development, we
have studied the expression of bcl-2 in a variety of ovarian
tumours and in normal ovary. In those patients with malig-
nant tumours, we also correlated the expression with sur-
vival. Finally, expression was compared with the expression
of p53, another parameter of significance for survival in
ovarian cancer (Henriksen et al., 1994a) and perhaps of
significance for the apoptotic process (Yonish-Rouach et al.,
1991).
Materials and methods
Patient material
In this prospective study samples were obtained at operation,
frozen immediately and kept at - 7OC until analysed. Speci-
mens were obtained from 50 malignant epithelial ovarian
tumours (details in Table I), ten borderline and 12 benign
ovarian tumours and from nine normal ovaries. None of the
patients had been subject to treatment before surgerv. In
most cases total hysterectomy, bilateral salpingoophorectomy
and extirpation of the greater omentum was included in the
surgical procedure for all stages. Four selected cases with
early stage I tumours received no chemotherapy, whereas the
others were treated with 4-6 adjuvant cycles of cisplatin and
doxorubicin. With few exceptions, patients with stage II-IV
tumours underwent 8-10 cycles of cisplatin and doxorubicin
as a first line of treatment. Paraplatin or 5-FU and
leucovorin were chosen as second-line treatment. Mean
follow-up time was 39 months (range 5-60 months); 85%
had been followed for more than 2 years. Deaths and cen-
sored values in the examined subgroups are shown in the
figures.
Immunohistochemistrjv
Immunohistochemical stainings were performed using 6 mm
thick cryosections. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide and endogenous
avidin-binding activity was blocked using a Blocking kit
(Vector Laboratories, Burlingame, CA, USA). After incuba-
tion with normal horse serum to block unspecific binding,
primary antibody was applied and the sections incubated
overnight at 4°C in a humidity chamber. As the primary
antibodies, the mouse monoclonal anti-bcl-2 antibody 124
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1995Table I Malignant ovarian neoplasms grouped according to
histopathological type and FIGO stage
Stage
Type I II III IV Total
Serous 2 1 13 2 18
Mucinous 5 0 3 1 9
Endometrioid 4 2 6 0 12
Clear cell 5 1 0 0 6
Undifferentiated 0 0 1 0 1
Mixed 2 1 1 0 4
Total 18 5 24 3 50
Bd-2 inMaruan neopasms
R Henrksen etal i
1325
diluted 1:200 (Cambridge Research Biochemicals) or the
mouse monoclonal anti-p53 antibody PAb 1801 diluted 1:20
were used. After washing in PBS, biotinylated horse anti-
mouse Ig (Vector) served as the secondary antibody and the
immunoreaction was visualised with a Vectastain Elite ABC
kit (Vector) using ethylcarbazole or diaminobenzidine as the
chromogen. Finally, the sections were briefly counterstained
in Meyer's haematoxylin. All samples had been classified by
the same pathologist (EW) using the FIGO classification.
Samples were graded as unstained, weakly or strongly cyto-
plasmic stained with respect to staining of epithelial cells in
normal ovaries and tumour cells in the neoplastic groups.
Microscopy and evaluation were performed independently by
two of the authors. In a few cases with minor disagreement
in evaluation, samples were studied together before final
classification.
Statistical analvsis
Survival was measured from the time of primary operation
and survival curves constructed by the methods of Kaplan
and Meier (1958). Significance was estimated by the log-rank
test (Mantel. 1966). Differences in growth factor expression
between the groups were estimated with the two-tailed Fisher
exact probability test (Armitage, 1987).
Results
Expression ofbcl-2 in ovarian epithelial cells and in twnour
cells in benign borderline andmalignant neoplasms
To examine the significance of bcl-2 in ovarian tumour
development we stained several ovarian tumours of varying
degrees of malignancy as well as normal ovaries with a
monoclonal antibody to bcl-2 protein, which has been used
in other studies (Colombel et al., 1993; Pezella et al., 1993;
Leek et al., 1994). The results are summarised in Table II. In
nine ovaries all epithelial cells stained strongly (Figure 1). In
contrast, benign ovarian tumour cells showed no expression
in two samples, two were weakly and the remaining eight
strongly stained (Figure 2). Of ten borderline tumours one
showed no expression and five were weakly and four strongly
stained. A corresponding distribution was found in 50 malig-
nant tumours. where 10 tumours did not contain
immunoreactive tumour cells, while weak and strong expres-
sion were observed in 16 and 24 samples respectively (Figures
3 and 4). Thus, the same pattern of decreased expression in a
Table H Positive bcl-2 staining of ovarian epithelial cells and
benign or malignant ovarian tumour cells
0 1 2
Normal ovary 0 0 9
Benign tumours 2 2 8
Borderline tumours 1 5 4
Malignant tumours 10 16 24
Expression was graded 0-2 corresponding to no staining, weak or
strong staining (P=0.02 and 0.01 for bcl-2 = 0 or bcl-2 = I
compared with bcl-2 =2 in the borderline and malignant groups vs
the normal ovaries).
Fugwe 1 Bcl-2 staining of a normal ovary illustrating the strong
staining of the normal epithelium.
Figwe 2 Bcl-2 staining of a mucinous ovarian cyst showing an
almost negative staining of the benign tumour oeUs.
I
*.
E
Fige 3 Bcl-2 staining of an ovarian clear cel carcinoma show-
ing a generally strong staining of the malignant tumour cels.
Figwe 4 Bcl-2 staining of an endometrioid highly differentiated
ovaran cancer. A varying expression from completely negative,to strongly positive malignant tumour ceUls is seen.a B-d-2 in oanr neoplasm
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substantial fraction of cases compared with ovarian
epithelium was observed in the tumour groups, and the
differences were significant for both the borderline (P = 0.02)
and malignant groups (P = 0.01).
Subsequently, tumour staining was compared with the
known risk factors stage, residual tumour bulk and
differentiation (Table III). While no relation between the
presence of bcl-2 and dissemination or differentiation of
tumours could be detected, decreased expression was
observed significantly more often in patients with residual
tumour tissue after primary operation compared with
radically operated ones (P = 0.03 and P = 0.003 for weakly
and strongly stained groups respectively).
Expression ofbcl-2 in the stroma in benign, borderline and
malignant neoplasms
Positive stromal staining was observed in most samples in all
groups. Normal ovaries were strongly stained in the cortical
parts and only weakly in the core. The tumour groups
showed varying staining with no difference between them
(results not shown).
Comparison ofbcl-2 expression in malignant ovarian tumour
cells with survival
The decreased expression of bcl-2 in ovarian neoplasms com-
pared with ovarian epithelium led us to examine its potential
correlation with survival. As shown in Figure 5 there was a
stepwise and highly significant correlation with survival.
Among the group whose tumours stained strongly, 81% were
alive at the end of the observation period while for those
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Fgre 5 Survival in 50 patients with ovarian cancer, according
to expression of bcl-2 in tumour cells. The P-value was deter-
mined with the log-rank test. Tick marks indicate censored
values. Bcl-2 = 0: no staining. Bcl-2 = 1: weak staining. Bcl-2 = 2:
strong staining.
Table III Expression of bcl-2 related to stage, residual tumour bulk
and differentiation
0 1 2
Stage I 2 6 10
Stage II 1 1 3
Stages III-IV 7 9 11
No residual tumour bulk 1 9 17
Residual tumour bulk 8 7 7
Highly differentiated 3 2 7
Moderately differentiated 5 6 8
Poorly differentiated 2 7 4
Expression was graded 0-2 corresponding to no staining, weak or
strong staining (P = 0.03 and P = 0.003 for bcl-2 = I and 2
respectively in those having residual tumour mass compared with
patients macroscopically tumour-free after operation).
with weakly stained and unstained neoplasms, 52%
(P=0.02) and 20% (P<0.001) were alive respectively. The
difference was even significant between the weakly and uns-
tained groups (P= 0.03). This correlation is of the same
magnitude as stage (Figure 6), residual tumour bulk (Figure
7) and the new biological prognostic parameter platelet-
derived growth factor alpha (PDGF-() receptor (Henriksen
et al., 1993). The strength of bcl-2 as a prognostic marker
was tested by relating staining to survival in the subgroups
with advanced disease (Figure 6) or residual tumour bulk
(Figure 7). For patients in stages III or IV the decreased
survival was retained for unstained vs strongly stained groups
(Figure 6, P= 0.002). When patients with residual tumour
bulk were stratified for bcl-2 expression in tumour cells
significance was found between strongly and unstained
groups (Figure 7, P = 0.03).
Expression ofbcl-2 compared wvith expression ofp53 in
malignant neoplasms
The details and significance of p53 expression in ovarian
tumours are given in an earlier report (Henriksen et al..
1994a). Briefly, almost half of the malignant ovarian tumours
stained positive for p53. and positive immunoreactivity was
correlated with prognostic variables such as dissemination of
disease and residual tumour bulk. Furthermore, positive
tumour cell staining correlated with shorter survival in the
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Fugwe 6 Survival in patients with ovarian cancer in stage I-II
or III-IV according to expression of bcl-2 in tumour cells. The
P-value was determined with the log-rank test. Tick marks
indicate censored values. Bcl-2 = 0: no staining. Bcl-2 = 1: weak
staining, Bcl-2 = 2: strong staining.
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Figure 7 Survival in patients with ovarian cancer and residual
tumour bulk after primary operation according to expression of
bcl-2 in tumour cells. The P-value was determined with the
log-rank test. Tick marks indicate censored values. Bcl-2 = 0: no
staining, Bcl-2 = 1: weak staining, Bcl-2 = 2: strong staining.
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subgroup of patients with residual tumour bulk. As seen in
Table IV an inverse relation between the expression of bcl-2
and p53 was observed. In line with the above observations
those patients having p53 positive tumours also positive for
bcl-2 experienced significantly better survival compared with
the bcl-2-negative counterparts (Figure 8).
DhF~
Bcl-2 oncoprotein was initially described as a result of the
chromosomal translocation t(14;18) observed in a large
number of follicular B-cell lines (Tsujimoto et al., 1985). The
resultant overexpression of bcl-2 often conferred on the
affected lymphocytes a resistance to apoptosis (Vaux et al.,
1988). Later, however, bcl-2 expression was found in normal
lymphoid cells and a number of lymphoproliferative
disorders without t(14;18) translocation (Pezella et al., 1990)
and recently. bcl-2 expression was detected in several non-
lymphoid tissues (Hockenbery et al., 1991).
Ultrastructurally, it was first localised to the inner
mitochondrial membranes (Hockenbery et al., 1990), but
immunoelectron microscopy has demonstrated bcl-2
immunoreactivity to the outer mitochondrial membrane and
nuclear envelope and to a lesser degree to the cell membrane
(de Jong et al., 1994).
The mitochondrial localisation indicated a physiological
function mediated via the metabolic functions of this organ-
elle. However. bcl-2 studies on human mutant cell lines that
lack mitochondrial DNA suggest that neither apoptosis nor
the protective effect of bcl-2 depends on mitochondrial res-
piration (Jacobsson et al., 1993). Other possible functions
such as involvement in transmembrane transport have
hitherto been purely speculative (de Jong et al., 1994), but
recent evidence indicates a regulating function of endoplas-
mic reticulum-associated Ca2+ fluxes (Lam et al., 1994).
Thus, overall, the physiological functions and metabolic
pathways remain to be elucidated.
With respect to carcinogenesis the results of the present
study on ovaries and ovanran tumours indicate an inhibitory
.-
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F re 8 Survival in patients having p53 iinmunoreactive malig-
nant ovarian tumours according to expression of bcl-2. The
P-value was determined with the log-rank test. Tick marks
indicate censored values. Bcl-2 =0- 1: no or weak staining, Bcl-
2 = 2: strong staining.
Table IV Expression of bcl-2 compared with p53 in malignant
ovanan tumours
p53 Negative Positive
Bcl-20-1 11 15
Bcl-2 2 16 8
Expression was graded 0-2 corresponding to no staining, weak or
strong staining (P = 0.07 for strongly stained vs weakly or negatively
stained tumours).
role for bcl-2. Thus, while ovarian epithelium always ex-
pressed this oncoprotein, a decreased staining in tumour cells
was demonstrated in all tumour groups, which was of the
same order of magnitude (Table II). The positive epithelial
staining is in line with observations in normal human breast
(Hockenbery et al., 1991; Leek et al., 1994), prostate (Hockenbery et al., 1991; Colombel et al., 1993) and thyroid gland (Hockenbery et al., 1991). In the gastrointestinal tract
positive staining was restricted to stem cells and proliferative
zones (Hockenbery et al.. 1991).
Furthermore, bcl-2 expression correlated significantly with
survival such that decreasing survival paralleled the decreased
expression in tumour cells (Figure 5). The strength was fur-
ther evaluated by studying the subgroups of patients with
advanced disease or residual tumour bulk, both of which are
strong clinical prognostic parameters. In both these sub-
groups, too, survival was significantly correlated with bcl-2
staining, which underscores an independent role in tumour
development and,or progression. In line with our results are
the recent observations in non-small-cell lung cancer (Pezella
et al., 1993) and breast carcinoma (Silvestrini et al., 1994),
where expression of this oncoprotein correlated with survival.
In other recent works the staining in tumour cells was
decreased in breast carcinoma compared with normal breast
epithelium, but no survival data were reported (Leek et al.,
1994; Nathan et al., 1994). High levels of bcl-2 in cells
derived from several cancers resulted in profound growth
inhibition while a COOH-terminal deletion mutant of bcl-2
had no effect (Pietenpol et al., 1994). In contrast, in human
prostate cancers, and especially those refractory to androgen
treatment, a stronger bcl-2 staining than corresponding
epithelium was noticed and led the authors to suggest a
relation to androgen-resistant prostate cancer (Colombel et
al., 1993). Thus, bcl-2 may serve different functions in the
pathobiology of different tissues.
The reason for the correlation of bcl-2 expression with
better survival is unknown. According to one theory derived
from a study of bcl-2-immunoglobulin transgenic mice
(McDonnell et al., 1989) bcl-2 may provide a survival advan-
tage to slowly growing tumour cells and thereby decrease the
risk of further genetic changes resulting in less aggressive
tumours. We have found that proliferation in ovarian cancer
estimated by expression of Ki-67 or the S-phase fraction is of
strong prognostic significance (Henriksen et al., 1994b). How-
ever, no correlation was observed between the expression of
bcl-2 and these proliferation variables (results not shown),
and thus the survival advantage of bcl-2 does not seem to
depend on a low degree of proliferation.
The human ovarian surface epithelium undergoes cyclic
changes of importance for the ovarian function. After ovula-
tion this inconspicuous serosa-like cell layer undergoes rapid
proliferation and migrates to cover the site of follicular rup-
ture. However, the regulatory cellular mechanisms are not
known in detail.
Also the role and need for apoptotic mechanisms in
ovarian epithelial physiology are completely unknown. There
is general agreement that epithelial ovarian tumours develop
from ovarium epithelium. It is believed that repeated pro-
liferative activity among the epithelial cells predispose to
genetic damage and to malignant conversion. Apoptosis
might be an effective antineoplastic mechanism by
eliminating damaged or transformed cells. Therefore, loss of
function should be expected to act in a tumorigenic way.
However, our results and those of others (Pezella et al., 1993; Silvestrini et al., 1994) with bcl-2 staining indicate the
opposite effect with decreased survival correlating with
decreased expression in tumour cells. Furthermore, staining of normal ovaries and benign and borderline tumours
revealed reduced expression in a number of both tumour
groups, indicating that this oncoprotein expression may be
depressed at an early stage of tumour development. Whether
this plays an early pathogenic role is unknown. Does
decreased bcl-2 staining define a group of benign tumours
with a particular propensity to progress to malignancy? Sup-
port for such a subgroup is found in our recent report
1327Bd-2 inowian neopris
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showing expression of Ki-67 in a few benign ovarian
tumours, which suggest proliferative activity in a subgroup of
benign ovarian tumours (Henriksen et al.. 1994b). Our
knowledge of ovarian tumours is mainly restricted to his-
topathology. In general not much is known of the biological
aspects and, in particular, time-related changes are unknown.
Recently. bcl-2 was shown to prevent p53-induced apop-
tosis at the permissive temperature in rodent cells trans-
formed with ElA plus a p53 temperature-sensitive mutant
(Chiou et al., 1994). While bcl-2 diverted the activity of
wild-type p53 from apoptosis to induction of growth arrest,
it did not affect the localisation or the levels of p53 indicating
an effect downstream of the tumour-suppressor gene product.
In other recent reports the same group presented evidence for
a p53-inducible decrease of bcl-2 and increase of bax expres-
sion (Miyashita et al., 1994a; Selvakumaran et al., 1994) and
for a p53-dependent negative response element in the bcl-2
gene (Miyashita et al., 1994b). This might be expected to
result in an inverse expression of p53 and bcl-2, and this has
been reported in normal tissues (Pezella et al.. 1994) as well
as in mammarian tumours (Silvestrini et al., 1994) and in the
present work, too, an inverse correlation was found. How-
ever, while an interaction with bcl-2 function is supposed to
exist with the wild-type form of p53, not much is known of a
corresponding function with the different mutational forms
of the protein. In one report overexpression of mutant p53
could induce down-regulation of bcl-2 both at mRNA and
protein level (Haldar et al., 1993). Whether this is valid in
our material remains to be elucidated.
The number of patients in our study does not allow a
multivariate analysis. To elucidate the possible significance of
bcl-2 independently of p53, the correlation with survival in
the p53-positive group was examined. As seen in Figure 8 a
significant correlation between bcl-2 expression and survival
was still detectable which underlines that the observed cor-
relation between bcl-2 expression and survival is not secon-
dary to mutational inactivation of p53. In the group
negatively stained for p53 the material was too small to make
similar statistical estimations.
In conclusion, we have reported a strong epithelial staining
of bcl-2 in ovaries and a reduced tumour cell immunoreac-
tivity in benign, borderline and malignant epithelial ovarian
tumours. Overall, the expression in malignant tumours
strongly correlated with enhanced survival, which was also
observed in subgroups of patients with advanced disease or
residual tumour bulk as well as in patients having p53-
positive tumours, indicating an independent role in ovarian
carcinogenesis.
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